Search

everythinglearnresearchcommunity

for

Search:↓

The conclusion is that individual differences in COVID-19 severity are influenced by factors like age, sex, race, and genetics, which are important for personalized medicine.

Keratins are important for skin cell health and their problems can cause diseases.

New treatments for Hepatitis C show promise but need more research to confirm their safety and effectiveness for clinical use.

Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.

Androgenetic alopecia linked to COVID-19 severity; drugs reducing androgen receptor activation may help.

Understanding the genetics of rare inherited ichthyosis syndromes is key for better treatments and genetic counseling.

Low-potency steroids can cause serious side effects in people with skin conditions like Netherton syndrome.

5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.

Spironolactone might help protect against severe lung problems in COVID-19 patients.

Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.

AGA linked to worse COVID-19 outcomes in men.

Recent genetic insights show that low-renin hypertension includes a range from essential hypertension to secondary or familial forms, affecting diagnosis and treatment.

Genetic marker rs12558842 strongly linked to male hair loss.

Having a lot of gray hair and hair loss are linked to more severe COVID-19.

A certain genetic variant in the androgen receptor may predict the severity of COVID-19 in men.

A mutation in the Soat1 gene causes hair structure defects and other health issues in AKR/J mice.

Procyanidins from grape seeds reduce nerve pain by blocking specific proteins and inflammation.

Testosterone may have a dual role in COVID-19, potentially worsening outcomes in men, and testosterone therapy could help some patients, but more research is needed.

Antiandrogen drugs can reduce PSA levels in women with excess hair, suggesting PSA is a sign of male hormone activity in women.

COVID-19 and hypopituitarism (reduced pituitary gland function) are linked, with the latter's related health issues potentially worsening COVID-19 outcomes, and COVID-19 possibly increasing risk for pituitary complications.

Clascoterone is a new, effective, and safe acne treatment without systemic side effects.

COVID-19 may affect male fertility and women might have better outcomes due to hormonal and immune differences.

COVID-19 patients may experience hair loss, but it's not linked to their age or sex.

The medication lopinavir-ritonavir may cause severe hair loss.

Understanding how androgens work is key for creating new treatments for prostate issues and hair/skin conditions.

COVID-19 may worsen with androgens; anti-androgen drugs could help.

PSA levels are higher in women with PCOS, but FAI is a more accurate marker for diagnosis.

5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.

Six African American women experienced hair loss after switching to a new HIV medication.

Certain mutations in the PADI3 gene may increase the risk of developing a type of scarring hair loss common in women of African descent.